OrbiMed launches $600M fund for royalty, debt deals

OrbiMed, a big venture investor in the biotech industry, has assembled a $600 million fund to lure life sciences companies looking for some quick cash on royalty streams or a fresh source of debt capital. And they're styling the new deal-making group as a ready alternative to equity markets.

"Life sciences companies are typically dependent on equity markets to raise new capital," said Tadd Wessel, a managing director on the "Royalty Opportunities" team. "With this fund, OrbiMed can offer a minimally dilutive capital alternative to fund product launches, M&A opportunities, new product research and general corporate purposes."

The fund will be operated by three OrbiMed partners--Samuel D. Isaly, Sven H. Borho and W. Carter Neild--and a dedicated team which includes Tadd S. Wessel, Matthew S. Rizzo, Matthew L. Wotiz and J. Christopher LiPuma.

- see the OrbiMed release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.